Grifols, S.A. (NASDAQ:GRFS) Short Interest Update

Grifols, S.A. (NASDAQ:GRFS) was the recipient of a large drop in short interest during the month of January. As of January 31st, there was short interest totalling 3,130,000 shares, a drop of 10.8% from the January 15th total of 3,510,000 shares. Currently, 1.2% of the company’s shares are sold short. Based on an average daily trading volume, of 1,030,000 shares, the days-to-cover ratio is presently 3.0 days.

Grifols Price Performance

GRFS stock traded up $0.06 during trading on Tuesday, reaching $7.38. The company had a trading volume of 890,787 shares, compared to its average volume of 787,151. The business has a 50 day moving average of $7.38 and a 200 day moving average of $8.09. The company has a debt-to-equity ratio of 1.11, a current ratio of 2.26 and a quick ratio of 0.79. Grifols has a 52 week low of $5.30 and a 52 week high of $9.96.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. R Squared Ltd bought a new stake in shares of Grifols during the fourth quarter valued at approximately $28,000. GAMMA Investing LLC lifted its position in Grifols by 49.4% during the third quarter. GAMMA Investing LLC now owns 3,432 shares of the biotechnology company’s stock valued at $30,000 after buying an additional 1,135 shares during the period. Signaturefd LLC boosted its holdings in shares of Grifols by 66.2% during the 3rd quarter. Signaturefd LLC now owns 5,407 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 2,153 shares in the last quarter. Blue Trust Inc. boosted its holdings in shares of Grifols by 254.0% during the 4th quarter. Blue Trust Inc. now owns 6,927 shares of the biotechnology company’s stock valued at $52,000 after buying an additional 4,970 shares in the last quarter. Finally, Tower Research Capital LLC TRC grew its position in shares of Grifols by 354.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 8,124 shares of the biotechnology company’s stock worth $60,000 after buying an additional 6,335 shares during the period.

Analyst Upgrades and Downgrades

GRFS has been the subject of a number of recent analyst reports. Morgan Stanley initiated coverage on Grifols in a report on Wednesday, February 12th. They set an “overweight” rating for the company. Berenberg Bank raised shares of Grifols to a “strong-buy” rating in a research report on Tuesday, October 29th.

Grifols Company Profile

Grifols, SA operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand’s disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease.